Implanon Insertion is Safe and Appropriate in This Patient
Yes, you can safely insert the etonogestrel implant (Implanon) in this patient at 2 months postpartum. Graves disease on carbimazole is not a contraindication to the etonogestrel implant, and the implant is compatible with breastfeeding at this timepoint.
Key Clinical Reasoning
No Contraindication from Graves Disease or Carbimazole
The etonogestrel implant has very few absolute contraindications (US MEC Category 4), with only current breast cancer being listed 1. Graves disease is not mentioned as a contraindication in the SMFM guidelines, and LARC methods are Category 1 or 2 for most medical conditions 1.
Regarding carbimazole specifically:
- The US MEC guidelines address anticonvulsants that may reduce progestin-only contraceptive effectiveness, but carbimazole is not among the drugs that interact with etonogestrel implants 2
- No drug interactions between antithyroid medications and progestin-only contraceptives are documented in the evidence
- Carbimazole's mechanism (blocking thyroid hormone synthesis) does not interfere with progestin metabolism
Breastfeeding Compatibility at 2 Months Postpartum
At 2 months postpartum, breastfeeding is well-established and the implant poses minimal concerns:
- Immediate postpartum insertion (within 48 hours) does not alter breast milk volume in randomized trials 3
- While one pilot study showed biochemical markers suggesting delayed secretory activation with very early insertion 4, this is not clinically relevant at 2 months when lactation is already established
- The infant's daily steroid intake from breast milk is minimal (75-120 ng of etonogestrel) 5
- Exclusive breastfeeding rates and infant weight gain are similar between implant users and non-users 3, 6
Additional Benefits in This Clinical Context
This patient has specific risk factors making LARC particularly beneficial:
- History of emergency LSCS - preventing short interpregnancy interval is crucial for uterine healing
- Active medical condition (Graves disease) - avoiding unintended pregnancy while managing thyroid disease is important
- LARC methods are estrogen-free, making them safer than combined hormonal contraceptives for women with medical complexity 1
Practical Implementation
- Insert the implant at the 2-month postpartum visit without delay
- No need to adjust carbimazole dosing
- Continue monitoring thyroid function as clinically indicated for Graves disease management
- Reassure the patient that the small amount of progestin in breast milk poses no risk to the infant
- The implant provides 3 years of highly effective contraception (>99% efficacy)
Common Pitfall to Avoid
Do not unnecessarily delay insertion due to unfounded concerns about drug interactions or breastfeeding effects. The evidence clearly supports safety at this timepoint, and delaying increases the risk of unintended pregnancy during a period when pregnancy would be medically suboptimal given her recent LSCS and ongoing Graves disease management.